Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Jun 11, 2021 5:23pm
233 Views
Post# 33376549

RE:Poking myself in the eye each day with TH

RE:Poking myself in the eye each day with THThey have a big problem on this front in that they have made projections about future revenues in the past for Egrifta in lipo and Trogarzo and then they came up well short of those forecasts. So, they have a credibility issue regarding forecasts. They might decide to give us some new forecasts for cancer on 6/21 but will the market even react to that like it does to the other companies you are following? Probably not due to their los credibility. Besides, it is too early to discuss such matters on cancer, although guidance about the market sizes they could get involved in with TH-1902 would be helpful so investors can start to understand the upside possibilities. They will still need to make a detailed market forecast at some point but they then also need to come somewhere close to it to regain investor credibility. I am certain they are not anywhere near making any specific revenue forecasts about cancer or NASH yet, nor should they be.

But they can start trying to rebuild their credibility by announcing Egrifta in Lipo and Trogarzo  sales guidance, which is below what they are confident they can actually achieve. That would force the analysts who are carrying goofy forecasts to fix their numbers and would put them in a place where the next time they report earnings the headline is they beat on revenues and they beat on earnings, which should be the goal. Once a company gets a reputation for consistently doing that, the stock typically benefits as analysts will have greater confidence that the company will not blow them up in the future as THTX has consistently done to the analysts in the past.   



realitycheck4u wrote: All of my investments I've been decided on the potential future including TH. However all of my other investments talk about the future revenue potential except TH. So why would anybody who does not have the time to actually read between the lines invest in TH when it should be TH who tells me what their success should financially mean to the company yet TH does not do that. That's their problem. They don't know how to get people excited about the potential future with real numbers as the hypothetical potential. 


<< Previous
Bullboard Posts
Next >>